Interleukin-2 (IL-2) and interferon-alpha (IFN-α) were among the first cytokines used in oncology, showing clinical benefit in subsets of patients with metastatic melanoma and RCC by enhancing cytotoxic immune activity. This evidence concerns the gene IL2 and metastatic melanoma.